Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kronenberger, K.
Right arrow Articles by Mocikat, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kronenberger, K.
Right arrow Articles by Mocikat, R.
Related Collections
Right arrow Neoplasia
Right arrow Immunotherapy
Right arrow Gene Therapy
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 15 February 2002, Vol. 99, No. 4, pp. 1327-1331

NEOPLASIA

Impact of the lymphoma idiotype on in vivo tumor protection in a vaccination model based on targeting antigens to antigen-presenting cells

Konrad Kronenberger, Andreas Dieckmann, Michael Selmayr, John Strehl, Ulrich Wahl, Horst Lindhofer, Georg Kraal, and Ralph Mocikat

From GSF-Institut für Molekulare Immunologie, Munich, Germany; GSF-Institut für Klinische Molekularbiologie und Tumorgenetik, Munich, Germany; Department of Molecular Cell Biology, Vrije Universiteit, Amsterdam, The Netherlands; and Medizinische Klinik der Universität Bonn, Germany.

Trioma cell vaccination is a potent new immunologic approach for the therapy of malignant B-cell lymphoma. It is based on targeting tumor antigens to internalizing receptors on antigen-presenting cells (APCs). Tumor cells are fused to an APC-specific hybridoma, where they are converted to trioma cells that include potentially all lymphoma-derived antigens and that express the APC-binding arm. In this study, the mechanisms of trioma-mediated tumor immunity in immunocompetent mice were dissected, and it was shown in this model system that humoral anti-idiotypic immunity is indeed detectable after idiotype-specific immunization but that it does not reflect the degree of tumor protection obtained in vivo. Immunization against the idiotype alone was not sufficient for efficient tumor rejection in vivo. Targeting tumor antigens to APCs is only successful in terms of inducing tumor protection when designed as a polyvalent vaccination protocol.

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
BloodHome page
C. Adam, S. King, T. Allgeier, H. Braumuller, C. Luking, J. Mysliwietz, A. Kriegeskorte, D. H. Busch, M. Rocken, and R. Mocikat
DC-NK cell cross talk as a novel CD4+ T-cell-independent pathway for antitumor CTL induction
Blood, July 1, 2005; 106(1): 338 - 344.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S. Muraro, A. Bondanza, M. Bellone, P. D. Greenberg, and C. Bonini
Molecular modification of idiotypes from B-cell lymphomas for expression in mature dendritic cells as a strategy to induce tumor-reactive CD4+ and CD8+ T-cell responses
Blood, May 1, 2005; 105(9): 3596 - 3604.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
U. Wahl, E. Nossner, K. Kronenberger, R. Gangnus, H. Pohla, M. S. Staege, H.-J. Kolb, M. Hallek, and R. Mocikat
Vaccination against B-cell Chronic Lymphocytic Leukemia with Trioma Cells: Preclinical Evaluation
Clin. Cancer Res., September 15, 2003; 9(11): 4240 - 4246.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020